Background. The quadrivalent (types 6, 11, 16, and 18) human papillomavirus (HPV) L1 virus-like-particle vaccine was 95%-100% effective in preventing cervical and genital disease related to Vaccine efficacy is thought to be mediated by humoral immunity. Here, we analyze the effect of the baseline characteristics of subjects on vaccine-induced immune responses.
Approximately 40 HPV types are known to infect the anogenital epithelium. These types are classified on the basis of their oncogenic potential. High-risk HPV types cause dysplastic lesions that can result in cancer. HPV-16 and -18 are the prototypes of this category. Together, these HPV types cause 170% of all cervical cancers worldwide [4] and a considerable amount of vaginal [5] , vulvar [6] , anal [7] , penile [8] , and head and neck cancers [9] . Low-risk HPV types cause low-grade dysplastic lesions, genital warts, and RRP but rarely cause cancer. HPV types 6 and 11 are the prototypes of this category. They are responsible for 90% of genital warts and RRP cases, as well as ∼10% of low-grade cervical dysplastic lesions [10] .
A vaccine that prevents infection and disease caused by HPV-6, -11, -16, and -18 will greatly reduce the burden of clinical HPV disease. Recent phase 2/3 trials have demonstrated that prophylactic administration of quadrivalent (types 6, 11, 16, and 18) vaccine to young women was 95%-100% effective in preventing cervical, vaginal, and vulvar dysplastic lesions (as well as anogenital condylomata) related to HPV-6, -11, -16, or -18 [11, 12] .
The quadrivalent HPV vaccine contains 4 types of virus-like particles (VLPs), each composed of the L1 major capsid protein of the relevant HPV vaccine type. In preclinical models of papillomavirus infection and disease, administration of L1 VLP vaccines induced robust serum antibody responses [13] [14] [15] [16] [17] . Vaccinated animals were protected from infection and disease, and this protective efficacy was a function of type-specific neutralizing antibodies. Unvaccinated animals that were given serum from vaccinated animals were also protected from infection and disease. In clinical trials, vaccine-induced anti-HPV was shown to neutralize high doses of live HPV-11 virions in a mouse xenograft assay [18] . Taken together, these data suggest that the efficacy of HPV L1 VLP vaccines is likely to be mediated by humoral immunity (i.e., circulating neutralizing anti-HPV antibodies).
High-throughput functional (neutralization) assays are not available for HPV. However, assays that measure serum anti-HPV responses that compete against monoclonal antibodies (MAbs) for binding to epitopes that are critical for virus entryand therefore limit detection of antibodies with neutralizing potential-have been developed. The advantage of using such assays relative to assays that measure the full spectrum of antibodies generated by the vaccine is that they may provide a more specific measure of immunogenicity that is related to protection against infection [19, 20] . Using these assays, phase 2/3 studies have shown that administration of quadrivalent HPV vaccine to preadolescent boys and girls and young adult women induces high-level type-specific anti-HPV responses [21] [22] [23] .
The efficacy and/or immunogenicity of vaccines and the pathogenicity of the organisms that they target can differ in subpopulations defined by race/ethnicity, behavior, age, and socioeconomic status. For example, Native American children have been found to be more susceptible to invasive Haemophilus influenzae type B (Hib) disease, and this susceptibility was inversely correlated with antibody responses to Hib vaccine [24] . Additionally, Hib vaccine-induced antibody responses were observed to be 3 times higher in Chilean infants than in Belgian infants [25] . Such differences may be due to genetic and/or environmental factors.
Because HPV infection is a global disease, prophylactic HPV vaccines such as the quadrivalent HPV vaccine will be used in diverse settings worldwide. Thus, it is important to evaluate the impact of demographic and behavioral parameters on the immunogenicity of the quadrivalent vaccine. In this analysis, we provide such an evaluation using a combined database of 6 phase 2/3 multinational trials of quadrivalent HPV vaccine that enrolled 12,343 subjects.
SUBJECTS, MATERIALS, AND METHODS
Study design and population. An analysis of the combined immunogenicity database of phase 2/3 studies submitted to regulatory agencies in support of the licensure of the quadrivalent HPV (types 6, 11, 16, and 18) L1 VLP vaccine (Gardasil; Merck), including 12,343 male and female subjects 9-26 years old enrolled in 6 phase 2/3 studies, was conducted (table 1) . The constituent studies contained 3 separate populations: virginal 9-15-year-old girls, virginal 9-15-year-old boys, and 16-26-year-old young women, most of whom were sexually active.
Eligible subjects received intramuscular (deltoid) injections of quadrivalent HPV vaccine or placebo at enrollment (day 1), month 2, and month 6. Each protocol was approved by the institutional review boards at each participating center. Detailed vaccine information and methodologies for protocols 007, 013, 015, 016, and 018 have been described elsewhere [11, 12, 21, 22, 26] .
Clinical follow-up. Subjects were enrolled between May 2000 and December 2002. Protocols 013, 015, and 018 are ongoing. All subjects underwent serological evaluation at day 1 and 1 month after dose 3. In protocols 007, 013, 015, and 018, subjects underwent serological evaluation at 6-24-month intervals, depending on the specific protocol.
Information on basic demographic characteristics was collected in all subjects. Among subjects who were 16 years old or older, information regarding sexual behavior and contraceptive use was collected, as were sexually transmitted infection, gynecologic, pregnancy, and lactation histories. Subjects 9-15 years old were to have been sexually naive at enrollment.
Immunogenicity assays. The immunogenicity of the quadrivalent HPV vaccine was measured using a competitive Luminex-based immunoassay (cLIA; developed by Merck Research Laboratories using technology from the Luminex Corporation) [27] . Antibody titers were determined in a competitive format in which known, type-specific, phycoerythrinlabeled neutralizing MAbs competed with the subject's serum antibodies for binding to conformationally sensitive neutralizing epitopes on the VLPs. The fluorescent signals from the bound HPV-specific detection MAbs are inversely proportional to the subject's neutralizing-antibody titers. Results for the assay were reported as concentrations of antibody in milli-Merck units per milliliter. The high, low, and negative controls used for this assay were spiked controls from heat-inactivated African green monkey serum diluted in antibody-depleted human serum. Statistical methods. Analyses were conducted in subjects meeting the per-protocol criteria. Briefly, the per-protocol immunogenicity (PPI) population included all subjects who were not general-protocol violators; received all 3 vaccinations within acceptable day ranges; were seronegative for vaccine HPV types at enrollment and, for all subjects except those !16 years old in protocols 016 and 018, were polymerase chain reaction (PCR) negative from day 1 through month 7 for the relevant HPV types; and had a month 7 serum sample collected within an acceptable day range. Although the PPI population excluded subjects who were seropositive for vaccine HPV types at baseline, a separate analysis was performed including these subjects to elucidate the differences in immune response between baseline seropositive and seronegative subjects. Analysis of subjects who were protocol violators for taking immunosuppressives or anti-inflammatory agents was performed in a modified PPI population whereby subjects conformed to all other requirements of the PPI population except that they had used these agents.
Geometric mean titers (GMTs) with associated 95% confidence intervals were determined and compared across categories of baseline subject characteristics. Cohorts analyzed included subjects given either quadrivalent vaccine or placebo stratified into the following 3 age/sex groups: 9-15-year-old males, 9-15-year-old females, and 16-26-year-old females.
Baseline covariates analyzed included age, sex, race/ethnicity, region of residence, hormonal contraceptive use, smoking status, lifetime number of sex partners, lactation status, baseline HPV seropositivity, body mass index (BMI), abnormal Pap test diagnosis, Chlamydia trachomatis infection, and immunosuppressant and anti-inflammatory usage.
Linear regression models were constructed using natural log titer at 1 month after dose 3 (month 7 blood draw) as the response variable, modeled as a function of 1 baseline covariate at a time. Regression models were based on the 18-26-yearold female cohort, because all covariates were available in that group. Enrollment age and BMI were treated as continuous variables in the regression models. Two types of modeling approaches were used. The single-factor approach modeled the type-specific month 7 natural log titer as a function of the individual baseline-predicting factor one at a time. The multiple-factor approach modeled the type-specific month 7 natural log titer as a function of several baseline-predicting factors at the same time. For the modeling of type-specific month 7 natural log titers using multiple predictors, a multifactor model was constructed that included all of the baseline factors that had P values !.2 in the single-factor approach. If the P values for both race/ethnicity and region met the .2 criterion in the single-factor model, only race/ethnicity was included in the multifactor model because of colinearity between race/ethnicity and region.
All of these evaluations were exploratory in nature; therefore, no statistical tests of hypotheses were performed. Nonoverlapping confidence intervals were used as the criterion of statistical significance.
RESULTS
The population included in the present analysis was ethnically diverse and resided in both developed and developing countries. Among the age/sex cohorts, basic characteristics were generally comparable between the placebo and vaccine groups (table 2) . Compared with the 16-26-year-old female population, the younger populations had a lower BMI and included more Asian subjects. Overall, 96% of subjects received all 3 doses of vaccine, and 95% of subjects either completed the study at month 7 or entered the long-term follow-up period (after month 7), depending on the study design of the trial in which they were enrolled. Principal reasons for exclusion from the PPI population included positivity to HPV vaccine types and generalprotocol violations (table 3) . Figure 1 summarizes the serum anti-HPV-6, -11, -16, and -18 responses 1 month after the completion of the vaccination regimen in girls and women, stratified by age at enrollment. For each of the 4 HPV types, month 7 GMTs decreased as the age at first vaccination increased. The declines in month 7 anti-HPV GMTs were steepest over the range of 9 to 15 years old at the initiation of vaccination. Among the adolescents, administration of the vaccine to boys resulted in higher anti-HPV-6, -11, -16, and -18 GMTs than girls of the same age, as seen previously (data not shown) [22] . Of note, prophylactic administration of the quadrivalent HPV vaccine to 16-26-yearolds was 100% effective in preventing HPV-16-and HPV-18-related CIN2/3 or AIS. Thus, the anti-HPV responses generated by the vaccine in adolescents were sufficient to induce highlevel protective efficacy.
Although small numeric differences in month 7 anti-HPV GMTs were observed among subpopulations defined by race/ ethnicity, no consistent pattern was demonstrated across all vaccine types (table 4). Subjects in North America tended to have higher anti-HPV GMTs than subjects in Latin America, Asia, and Europe. For each of the 4 HPV vaccine types, there were no significant differences in month 7 GMTs between subjects who used hormonal contraceptives during the vaccination period and those who did not. Subjects who received quadrivalent HPV vaccine and who were lactating at any time from day 1 to month 7 had higher anti-HPV-16 GMTs at month 7 than women who were not lactating.
The integrated immunogenicity data were also evaluated in a regression model to evaluate potential baseline characteristics that may influence the response to quadrivalent HPV vaccine (data not shown). In single-factor models, enrollment age was a significant predictor of month 7 anti-HPV-6, -11, -16, or -18 cLIA responses. The expected decreases in month 7 anti-HPV-6, -11, -16, and -18 natural log titers associated with increases in subject age at enrollment of 1 year were 0.024, 0.023, 0.045, and 0.043, respectively. This corresponds to 2.4%, 2.3%, 4.6%, and 4.4% decreases in the month 7 anti-HPV-6, -11, -16, and -18 GMTs, respectively. Race/ethnicity and region were also significant predictors of month 7 anti-HPV cLIA responses according to these models. For example, after adjusting for the effect of age, month 7 anti-HPV-6 natural log titers among subjects in Asia Pacific, Europe, and Latin America were 0.187, 0.097, and 0.153 lower, respectively, than those among subjects in North America. This corresponds to estimates of 20.6%, 10.2%, and 16.5% lower month 7 HPV-6 GMTs among subjects in Asia Pacific, Europe, and Latin America, respectively. Race/ethnicity and BMI were significant predictors of month 7 anti-HPV-11 titer; race/ethnicity and age were significant predictors of month 7 anti-HPV-16 titers; and race/ethnicity, age, and BMI were significant predictors of month 7 anti-HPV-18 titers. The month 7 anti-HPV-11 or -18 titers decreased with increases in BMI and age at enrollment. No baseline factors were predictive of changes in month 7 GMTs across all HPV vaccine types.
The clinical trials program enrolled subjects regardless of baseline HPV status. At the start of the program, it was postulated that subjects who had been exposed to a HPV vaccine type (i.e., became seropositive) before enrollment would generate higher levels of anti-HPV to that particular type after receipt of the quadrivalent HPV vaccine than would subjects who were naive to the relevant type. Table 5 displays the anti-HPV levels at month 7 in subject groups defined by day 1 HPV serostatus. Inclusion of subjects regardless of baseline HPV status permitted a comparison of vaccine-induced immune responses with those generated in response to an HPV infection. At all time points (data not shown), anti-HPV GMTs generated by the quadrivalent HPV vaccines were substantially higher than the levels observed in control subjects, who were seropositive at enrollment (resulting from exposure to HPV before enrollment) (table 5) .
DISCUSSION
The global burden of cervical cancer and other HPV-related diseases is substantial. Prophylactic vaccination using the quadrivalent (types 6, 11, 16, and 18) HPV L1 VLP vaccine is a promising new approach to reduce the burden of these diseases worldwide. This potential will be fully realized only if the capacity of the vaccine to induce robust anti-HPV responses (and protective efficacy) is not affected by variations in socioeconomic, ethnic, and behavioral characteristics of the target populations. The clinical trials of the quadrivalent HPV vaccine represent a crucial first step in evaluating the global impact of this vaccine. The studies enrolled a diverse population of subjects with a broad range of demographic and behavioral characteristics. The analysis presented here of immunogenicity in this integrated data set demonstrates that the immunogenicity of quadrivalent HPV vaccine is consistent across diverse populations, lending further support to the efficacy findings.
The quadrivalent HPV vaccine induced a robust immune response in persons of all ethnicities and across a broad range of socioeconomic circumstances. In these subpopulations, vaccine-induced anti-HPV levels were substantially higher than those observed in response to infection. Differences in humoral response subsequent to HPV vaccination have been previously observed with concurrent use of hormonal contraceptives [28] . Nardelli-Haefliger et al. [28] showed that hormonal contraceptive use by women immunized with HPV-16 VLPs resulted in consistently higher mucosal antibody levels than those in women who were ovulating. In that study, all participants developed detectable anti-HPV-16 VLP IgG levels measured in cervical secretions after immunization; however, cervical titers of specific IgG, total IgG, and IgA among participants in the ovulatory group varied considerably during the menstrual cycle.
Although the present study did not measure anti-HPV levels in cervical secretions, the combination of (1) the lack of interaction between contraceptive use and anti-HPV level and (2) the high efficacy of the vaccine suggests that potential variations in cervical anti-HPV IgG levels induced by ovulation are not likely to affect the efficacy of the vaccine.
The use of tobacco products has been shown to have an adverse effect on immune responses to viral pathogens. Studies have shown reductions in cervical densities of Langerhans cells and in levels of cell-mediated immune effector cytokines (such as interferon-g) among women who smoke, compared with those in nonsmokers [29] . Smoking has been directly correlated with a decreased probability of clearing an HPV infection, leading to increased persistence and risk of early cervical carcinogenic events [30] . Accordingly, cigarette smoking has been correlated with an increased risk of cervical cancer among HPVpositive women [30] . The absence of an interaction between serum anti-HPV level and smoking status at the time of first vaccination, combined with the high efficacy of the vaccine, suggests that prophylactic administration of the quadrivalent HPV vaccine will provide a high level of protection from infection and disease caused by HPV-6, -11, -16, and -18 in smokers. NOTE. This analysis population required that subjects had their month 7 serum sample collected within an acceptable day range. Titers are given in milli-Merck units (mMU) per milliliter. CI, confidence interval; PCR, polymerase chain reaction.
a A subject was defined as being seropositive for HPV-6, -11, -16, or -18 at day 1 if her corresponding anti-HPV cLIA titer was у20, 16, 20, or 24 mMU/mL, respectively. A subject was defined as being seronegative for HPV-6 or -11 only if she was seronegative for both HPV-6 and -11.
Implementation of vaccines against highly endemic disease typically includes routine vaccination of population segments before entry into the risk period, supplemented by universal catch-up vaccination campaigns aimed at people who are already at risk. The 10-year period after sexual debut represents the primary risk period for HPV infection. In most countries, the median age of sexual debut is in the range of 15 to 17 years. Thus, for prophylactic HPV vaccines, sexually naive adolescents represent a primary population for routine vaccination. The demonstration that vaccination of adolescents results in anti-HPV levels that are higher than those in young adults (the age range for which the high efficacy of the vaccine was demonstrated) suggests that routine vaccination of adolescents will be highly effective in reducing the burden of clinical HPV disease caused by HPV vaccine types.
Women in this analysis with detectable vaccine-type anti-HPV levels before immunization were shown to have a more robust humoral response against these types, characterized by a faster response, higher peaks, and increased persistence after administration of quadrivalent HPV vaccine relative to that in women who were HPV seronegative at baseline. This result not only suggests that exposure to HPV results in the generation of memory B cells but that these B cells are capable of an anamnestic response on restimulation with HPV antigens. Such responses may allow for long-term vaccine-induced immunity to HPV, either after a primary series or with booster vaccinations. These data are consistent with the previous findings of Villa et al. [23] and Poland et al. [31] , which suggested that vaccination with HPV VLPs were able to induce anamnestic responses.
Although this study provides an initial demonstration of the consistency of immunogenicity of the quadrivalent HPV vaccine, there are 3 important limitations to the present analysis that must be considered. First, although the study program enrolled subjects from 5 continents and included a substantial number of subjects of African descent, it did not enroll subjects from sub-Saharan Africa or South Asia. Given than these regions include populations with a substantial prevalence of factors that may interfere with vaccine-induced immune responses (e.g., HIV infection and poor nutrition), it will be important to evaluate the immunogenicity of the quadrivalent HPV vaccine in children and adults in these regions. Such trials are ongoing. Second, subjects in clinical trials tend to be healthier and more compliant with vaccination regimens than the general population. Thus, it will be important to evaluate the immunogenicity (and efficacy) of the quadrivalent HPV vaccine in population-based studies. Such studies are in the planning stages. Finally, although it is clear that the efficacy of prophylactic HPV vaccines is mediated by humoral responses, a minimum protective anti-HPV level or a postvaccination anti-HPV level that predicts the duration of protection has not been defined because of the high efficacy of the vaccine. Longer follow-up of the phase 3 studies described in this report may provide such a correlate.
In conclusion, we have shown that the immunogenicity of quadrivalent HPV vaccine is consistent across socioeconomic, ethnic, and behavioral strata. Taken together with the high prophylactic efficacy of the quadrivalent HPV vaccine, these findings suggest that population-based immunization programs that use this vaccine will result in substantial reductions in the burden of clinical HPV disease.
